Navigation Links
Abbott Announces 11 Percent Increase in Quarterly Dividend
Date:2/20/2009

Company Declares 341st Consecutive Quarterly Dividend

ABBOTT PARK, Ill., Feb. 20 /PRNewswire-FirstCall/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend 11 percent to 40 cents per share.

This marks the 37th consecutive year that Abbott has increased its dividend payout and the 341st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2009, to shareholders of record at the close of business on April 15, 2009.

Abbott has been named by a leading financial media outlet as one of its top five dividend stocks. Additionally, Abbott is a top performer of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
2. Abbott Announces Earnings Guidance for 2009
3. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
4. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
5. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
6. Abbott Hosts Conference Call for Third-Quarter Earnings
7. Abbott to Present at UBS Best of Americas Investment Conference
8. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
9. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
10. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
11. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. ... today announced the presentation of data at the San ... EPO-ANE-3010 study evaluating epoetin alfa plus best supportive care ... patients with metastatic breast cancer receiving standard chemotherapy. This ... was to rule out a 15 percent or greater ...
(Date:12/12/2014)... 2014 Graphite Metallizing Corporation, the manufacturer ... and process equipment, has appointed Kirk Staller as Sales ... Canada. Staller holds a B.S. degree from Purdue University ... market place, much of it with a manufacturer of ... Michigan office. , “We are pleased to ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2
... Tuesday, July 15 at 4:30 p.m. Eastern -, ... ), a molecular diagnostics company, will host a roundtable,teleconference ... Principal Investigator on the submission and Associate Professor of,Gynecologic ... keynote,speaker of the roundtable., Vermillion,s ovarian tumor triage ...
... LOS ANGELES and LONDON, July 11 Signalife,Inc. ... received board approval to proceed,with its previously-announced merger ... and that a specially-formed committee has been,appointed to ... to,completion of the transaction. As presently contemplated, a ...
... /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), a leading ... outsourcing company with operations in China and ... has won the 2008 Frost & Sullivan,Award ... Pharmaceuticals and,Biotechnology., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission 2Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission 3Signalife Board Approves Merger 2Signalife Board Approves Merger 3WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 2WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 3
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... available in French . , A study ... differences between individuals at the DNA level can lead ... These, in turn, are responsible for the vast array ... part of the Genome Regulators in Disease (GRID) Project ...
... the Tenovus Centre for Cancer Research at Cardiff University ... could help save the lives of women who become ... While drugs such as tamoxifen have been a huge ... of sufferers the drugs either fail to work, or ...
... Colloquium series will hold a meeting on gene ... program for the development of animal embryos, body ... focus on four areas -- gene regulatory networks ... developmental processes; regulatory processes in complex multigenic systems; ...
Cached Biology News:Tiny genetic differences have huge consequences: McGill researchers 2Further breakthroughs for breast cancer patients 2
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: